Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23,334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, Rasmussen J, Thornburg B, Berry WR, Wilder RS, Lu C, Chen Y, Silberstein JL, Kemeny G, Galletti G, Somarelli JA, Gupta S, Gregory SG, Scher HI, Dittamore R, Tagawa ST, Antonarakis ES, George DJ. Armstrong AJ, et al. Among authors: luo j. J Clin Oncol. 2019 May 1;37(13):1120-1129. doi: 10.1200/JCO.18.01731. Epub 2019 Mar 13. J Clin Oncol. 2019. PMID: 30865549 Free PMC article. Clinical Trial.
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J. Hu R, et al. Among authors: luo j. Cancer Res. 2012 Jul 15;72(14):3457-62. doi: 10.1158/0008-5472.CAN-11-3892. Epub 2012 Jun 18. Cancer Res. 2012. PMID: 22710436 Free PMC article.
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Antonarakis ES, et al. Among authors: luo j. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3. N Engl J Med. 2014. PMID: 25184630 Free PMC article.
Decoding the androgen receptor splice variants.
Lu C, Luo J. Lu C, et al. Among authors: luo j. Transl Androl Urol. 2013 Sep;2(3):178-186. doi: 10.3978/j.issn.2223-4683.2013.09.08. Transl Androl Urol. 2013. PMID: 25356377 Free PMC article.
Resistance to androgen-pathway drugs in prostate cancer.
Antonarakis ES, Nakazawa M, Luo J. Antonarakis ES, et al. Among authors: luo j. N Engl J Med. 2014 Dec 4;371(23):2234. doi: 10.1056/NEJMc1412594. N Engl J Med. 2014. PMID: 25470700 No abstract available.
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.
Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR. Schweizer MT, et al. Among authors: luo j. Sci Transl Med. 2015 Jan 7;7(269):269ra2. doi: 10.1126/scitranslmed.3010563. Sci Transl Med. 2015. PMID: 25568070 Free PMC article. Clinical Trial.
23,334 results
You have reached the last available page of results. Please see the User Guide for more information.